U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 16 results

Status:
Investigational

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Loxiglumide is a potent, orally active, and selective CCK-A receptor antagonist which stimulates calorie intake and hunger feelings in humans. Loxiglumide inhibits pancreatic secretion of digestive enzymes, and also blocks CCK-induced gastric secreti...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)



Patamostat (E-3123) is a protease inhibitor in vivo and in vitro. Inhibitory activity was shown toward trypsin, thrombin, plasmin, cathepsin-B and kallikrein. Patamostat is effective toward experimental pancreatitis and disseminated intravascular coa...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cycloheximide is an antibiotic produced by fermentation culture of Streptomyces griseus, Streptomyces noursei, Streptomyces albulus, Streptomyces naraensis, or other cycloheximide-producing microorganism. It was first discovered by A. Whiffen et al. ...
Status:
Investigational

Class (Stereo):
CHEMICAL (ACHIRAL)


Biologically, methanogens in the colon can use carbon dioxide and hydrogen to produce methane as a by-product. It was previously considered that humans do not utilize methane. However, in a recent study on rodents, results demonstrated that methane c...
Status:
Other

Class (Stereo):
CHEMICAL (ACHIRAL)


Conditions:

CID-2858522 is the potent and selective inhibitor of protein kinase C (PKC)-induced activation of the NF-κB pathway (IC50 < 0.1 μM for PMA-stimulated IL-8 production). CID-2858522 inhibits antigen receptor-stimulated NF-κB activation in chronic ly...
Sodium tauroglycocholate presents in ENZAR FORTE tablet, together with enzymes: amylase, lipase and protease. ENZAR FORTE is indicated for the treatment of the following digestive symptoms: indigestion/dyspepsia; flatulence; bloating; fullness after ...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ABSOLUTE)



Dexloxiglumide is a selective antagonist of cholecystokinin receptor A (CCKA, CCK1). It is the dextro isomeric form of loxiglumide, Dexloxiglumide was investigated for treatment of irritable bowel syndrome. Its development in USA was discontinued.
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)



Gabexate is a synthetic protease inhibitor, was shown to be effective in treating patients with sepsis-associated disseminated intravascular coagulation in which tumor necrosis factor-alpha (TNF-alpha) plays a critical role. Gabexate mesylate is a dr...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ABSOLUTE)



PRANAZEPIDE (FK480), a non-peptide CCK-A receptor antagonist developed in Japan. FK-480 was in phase II clinical trial for the treatment of pancreatitis or gastrointestinal disorders. No development was reported for Pancreatitis in Japan.
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ACHIRAL)



Nafamostat mesilate (NM), a synthetic serine protease inhibitor, has anticoagulant and anti-inflammatory properties. Nafamostat is approved and marketed in Japan. It relieves symptoms such as pain due to inflammation of the spleen. It improves viscer...

Showing 1 - 10 of 16 results